Next Article in Journal
A Potent Tyrosinase Inhibitor, (E)-3-(2,4-Dihydroxyphenyl)-1-(thiophen-2-yl)prop-2-en-1-one, with Anti-Melanogenesis Properties in α-MSH and IBMX-Induced B16F10 Melanoma Cells
Previous Article in Journal
Nuciferine Inhibits Proinflammatory Cytokines via the PPARs in LPS-Induced RAW264.7 Cells
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 23
Issue 10
10.3390/molecules23102724
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Review

Isoxazole Derivatives as Regulators of Immune Functions

by
Michał Zimecki
1,
Urszula Bąchor
2 and
Marcin Mączyński
2,*
1
Laboratory of Immunobiology, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Weigla 12, 53-114 Wroclaw, Poland
2
Department of Organic Chemistry, Faculty of Pharmacy, Wroclaw Medical University, Borowska 211a, 50-556 Wroclaw, Poland
*
Author to whom correspondence should be addressed.
Molecules 2018, 23(10), 2724; https://doi.org/10.3390/molecules23102724
Submission received: 4 October 2018 / Revised: 18 October 2018 / Accepted: 20 October 2018 / Published: 22 October 2018
(This article belongs to the Section Medicinal Chemistry)
Versions Notes

Abstract

In this review, we present reports on the immunoregulatory properties of isoxazole derivatives classified into several categories, such as immunosuppressive, anti-inflammatory, immunoregulatory, and immunostimulatory compounds. The compounds were tested in various models using resident cells from rodents and humans, cell lines, and experimental animal disease models corresponding to human clinical situations. Beneficial features of the described isoxazole derivatives include low toxicity and good bioactivity at low doses. In a majority of studies, the activities of investigated compounds were comparable or even higher than registered reference drugs. Whenever possible, a plausible mechanism of action of the investigated compounds and their potential therapeutic utility were proposed. Among the described compounds, particular attention was paid to the class of immune stimulators with a potential application in chemotherapy patients.

1. Introduction

Compounds containing the isoxazole ring [1] serve as an important source of valuable drugs that are designed to treat infections and diseases of different etiologies. Syntheses, classification, mechanisms of action, and the therapeutic application of registered isoxazole derivatives, as well as these under preclinical investigations, were recently in detail described in several reviews [2,3,4,5]. Therefore, we wished to focus in this short review only on data regarding the immunoregulatory properties of compounds containing the isoxazole ring. Although a majority of isoxazole derivatives under interest display immunosuppressive activities, including anti-inflammatory ones, less is known about immunostimulatory compounds of potential therapeutic utility. Such a group of compounds, besides immunosuppressive molecules, was also synthesized, and their potential therapeutic usefulness evaluated by our research team. In this review, the results regarding immunoregulatory actions of selected isoxazole derivatives in various immunological settings in vitro and in vivo human and rodent models are described (Table 1). In some investigations, the description of the immunoregulatory properties is accompanied with the suggested mechanism of action, and potential therapeutic applications are proposed.

2. Results and Discussion

2.1. Immune Suppression

Leflunomide and its active metabolite [6] are the most well-recognized immunosuppressive drugs, and they have found therapeutic applications if used alone or in combination with other drugs in rheumatoid arthritis [40] or transplantation [41]. As a prime representative of the isoxazole family, the drug is widely used as a reference drug to compare the potency of other investigated isoxazoles. Another example of a widely used isoxazole drug is Parecoxib, a pain reliever that acts as cyclooxygenase 2 (COX-2) inhibitor [7]. Its safety has been a subject of many multicenter trials, as summarized in a recent article [42], which could not definitely confirm the lack of its side effects reported earlier [43].
In investigations with rodents, a number of isoxazole derivatives was evaluated for their in vitro and in vivo immunosuppressive activities. In a study on the derivatives of isoxazole[4,5-d]pyrimidine [8], two compounds, 8g and 10f, inhibited the humoral immune response to sheep erythrocytes (SRBC) in vivo, but only one of them suppressed (10f) the delayed-type hypersensitivity response (DTH), showing that closely related compounds may differentially affect these two major types of immune response.
Suppressive properties of 5-amino-3-methylisoxazole-4-carboxylic acid amides and ureilenes [44], and 5-aminomethinimino-3-methyl-4-isoxazolecarboxylic acid phenylamides [9] on the humoral and cellular immune response in mice were subsequently found. One of the compounds, 5-(2-hydroxyethyl)piperazinomethinimino-3-methyl-4-isoxazolecarboxylic acid 4-(4-ethoxyphenyl)-amide (4d) [9] exhibited an exceptionally strong level of activity, comparable to cyclosporine. In turn, a study on the immunosuppressive activities of 5-substituted 3-methylisoxazole[5,4-d]-1,2,3-triazin-4-one derivatives [45], was supplemented with quantum-chemical calculations using AM1, a semi-empirical method for geometry optimization, the estimation of descriptor values, and the localization of the HOMO and LUMO orbital. The structure/activity investigations were extended by the application of the B3LYP hybrid exchange-correlation energy functional and the 6-31G(d, p) basis set. [46] The Polarizable Continuum (SCRF/PCM) solvent model was also taken into account, in order to show the solvent influence on the electron density, and the electrostatic potential around the exemplary molecules. Correlations between the molecular structure and its biological properties were subsequently found by using a stepwise selection of scales for the multiple linear regression (MLR).
The studies on an isoxazole[5,4-e]triazepine derivative (compound RM33) led us to a demonstration of the very potent immunosuppressive activities of the compound in mouse models [10,47]. The compound effectively suppressed both the humoral response to SRBC, and the cellular response to ovalbumin (OVA) when administered intraperitoneally or per os. The compound could also act locally by the inhibition of foot pad edema when admixed with Freund’s complete adjuvant. In addition, serum tumor necrosis factor alpha (TNF α) and interleukin 6 (IL-6) levels, induced by administration of lipopolysaccharide (LPS) were reduced, but not an inducible interleukin 10 (IL-10) concentration in splenocyte cultures. RM33 inhibited also foot pad edema that was induced by carrageenan in Wistar rats [48], accompanied by lower serum TNF α levels. The inhibition of the foot pad edema was correlated with adequate histological changes, such as a lesser level of damage to mast cells, and smaller macrophage infiltration. Very recent (unpublished data) indicate that the immunosuppressive action of RM33 may consist of its apoptotic action on thymocytes and splenocytes, associated with strong increases of caspase 9, p53, and NFκB1 and NFκB2 expression.
In another investigation of our group, a series of 5-amino-3-methylisoxazole[5,4-d]pyrimidin-4-one derivatives were obtained by the reaction of N′-substituted derivatives of 5-amino-3-methyl-1,2-oxazole-4-carbohydrazide with ethyl orthoformate [11]. The compounds differentially inhibited in vivo cellular and humoral immune responses in mice and pokeweed mitogen (PWM)-induced polyclonal antibody production in a culture of human peripheral blood mononuclear cells (PBMC). The derivatives displayed differential inhibitory activities in these models, depending on the character and location of the substituted groups. Also, a significant suppression of the in vivo humoral immune response to SRBC in mice was achieved upon low doses of 5-amino-3-methyl-4-isoxazolecarboxylic acid semicarbazides and thiosemicarbazides [12]. Other studies on new lead structures of the isoxazole system [13] revealed their strong immunosuppressive activities in the humoral immune response, the carrageenan model, and the proliferative response of lymphocytes. Density Functional Theory (DFT) was employed to shed light on the molecular properties of the investigated compounds. The geometrical parameters of the studied molecular structures were fully optimized at the B3LYP/6-311G (d, p) level. The atomic charge distribution, derived on the basis of the Mulliken population analysis, was correlated with the immunological activity of the compounds. The obtained relationships revealed that the isoxazole ring played an important role in the observed immunological activities.
In a study on 5-amino-3-methyl-4 isoxazolecarboxylic acid benzylamides [14] a selected MO5 compound (5-amino-3-methyl-N-[(4-methylphenyl)methyl]-1,2-oxazole-4-carboxamide) inhibited the humoral immune response in vitro and stimulated the inductive phase of DTH in vivo, although it suppressed the eliciting phase of that response and the foot pad carrageenan reaction. Its action on phytohemagglutinin A (PHA)-induced PBMC proliferation, and TNF α production was also inhibitory. In a parallel study [15], effects of 5-amino-3-methyl-1,2-oxazole-4-carbohydrazide on selective gene expression in Caco-2 cells were studied, together with Leflunomide (5-methyl-N-[4-(trifluoromethyl)phenyl]-4-isoxazolecarboxamide), as a reference drug. It appeared that both compounds similarly regulated selected genes i.e., the upregulation of fractalkine (CX3CL1) and IL-17F, and the downregulation of IL-10 and toll-like receptor 4 (TLR4). Nevertheless, the expression of 12 genes was differently regulated by these compounds: interleukins (IL) IL-1B, IL-6, and a chemokine CCL22 were upregulated by the compound, but significantly suppressed by Leflunomide. IL-2 and IL-27 in turn were upregulated by Leflunomide and suppressed by the compound. The authors concluded that the studied compound has a potential for further modifications as an immunosuppressive agent, with applications that are different from that of Leflunomide.
In a new series of N′-substituted derivatives of 5-amino-N,3-dimethyl-1,2-oxazole-4-carbohydrazide [16], a selected 5-amino-N′-[2-(2,4-dihydroxyphenyl)ethylidene]-N,3-dimethyl-1,2-oxazole-4-carbohydrazide (MM3 compound) lowered the PHA-induced proliferation of PBMC and LPS-induced TNF α production in human blood cell culture. In the model of Jurkat cells, MM3 elicited strong increases in the expression of caspases, Fas, and NF-κB1, indicating that a proapoptotic action may account for its immunosuppressive action in the studied models.

2.2. Inhibition of Inflammation

Izoxazole derivatives exhibiting anti-inflammatory properties constitute a major group from this class of potential therapeutics. In an early study [21] the authors demonstrated strong anti-inflammatory and antibacterial activity of p-etoxyphenylamid and p-chlorophenylamid of 5-benzoylamino-3-methyl-4-isoxazolecarboxylic acid. The most potent activity of these compounds were attributed to the benzoyl group in position 5 of the isoxazole ring.
HWA-486 (5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide), together with cyclophosphamide, a reference drug, was investigated in the model of adjuvant arthritis in Lewis rats [17]. The compound prevented the development of the disease and suppressed the mitogen-elicited proliferation of lymphocytes derived from adjuvant arthritis rats. In contrast to cyclophosphamide, the compound did not affect the proliferation of lymphocytes from healthy rats.
Leflunomide and its active metabolite A771726 [49] suppressed the immune response by means of various mechanisms [50,51]. In a model of J774.2 macrophages treated with LPS, both agents were shown to inhibit PGE2 accumulation in cell cultures. Further, in a whole blood human cell culture stimulated with calcium ionophore, Leflunomide inhibited both COX-1 and COX-2 activity [50]. In vivo effects of the compound were restricted by experimental substrate supply, and probably by plasma binding. Other important actions of A771726 include suppression of proinflammatory cytokine production, such as TNF α and IL-1 [51].
In an extensive study on in vitro, ex vivo, and in vivo immunopharmacological effects of VGX-1027 (S,R)-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid [22], the investigators evaluated the potential efficacy of the compound in the amelioration of acute and chronic immunoinflammatory diseases, based on its ability to inhibit LPS-induced cell signaling pathways. A lack of toxicity predisposes the compound for further preclinical investigations.
A potential utility of new fatty acid amine hydrolase (FAAH) inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffolds in protection against experimental colitis was recently also proposed [23].
A search for novel anticancer drug via inhibition of LOX and COX enzymes constitutes an important strategy, since the overproduction of leukotrienes and prostaglandins contributes to tumor growth by inducing formation of new blood vessels that support tumor cell growth. It was demonstrated [24] that one of the synthesized compounds, 5-(3-methylthiophen-2-yl)-3-(3,4,5-trimethoxyphenyl)-1,2-oxazole (2b) exhibited significant inhibitory activity toward lipooxygenase (LOX) and COX-2. 4,5-diarylisoxazol-3-carboxylic acids could also serve as leukotriene synthesis inhibitors [25], and thus they are potential anti-inflammatory drugs.
Macrophage migration inhibitory factor (MIF) is an inflammatory cytokine that is associated with inflammatory disorders, as only cytokine is resistant to steroid action. Airway hyper-responsiveness is also relatively resistant to steroid therapy. A MIF antagonist (S,R)-methyl [3-(4-oxocyclohexa-2,5-dien-1-ylidene)-1,2-oxazolidin-5-yl]acetate (ISO-1) [26] proved to be efficient in the suppression of lung inflammation in ozone-exposed mice, in contrast to Dexamethasone. MIF is also implicated in development of autoimmunity, so that the therapeutic efficacy of ISO-1 was also evaluated in a model of glomerulonephritis in lupus-prone NZB/NZW F1 and MLR/lpr mice [52]. The results showed that ISO-1, like anti-MIF, inhibited the interaction between MIF and its receptor, and reduced the functional and histological parameters of glomerulonephritis, leukocyte recruitment, proinflammatory cytokine and chemokine expression. These data support the therapeutic value of the compound by the downregulation of MIF-dependent pathways of tissue damage in systemic lupus erythematosus. For the prevention of another type of autoimmunity, (S,R)-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acid (VGX-1027) was tested in a model of NOD mice, with spontaneous or accelerated forms of diabetes induced either by injection of cyclophosphamide or by transfer of spleen cells from acutely diabetic syngeneic donors, representing a preclinical model of human type 1 diabetes mellitus [53]. The compound significantly diminished the cumulative incidence of diabetes and insulitis in this model. The animals receiving VGX-1027 exhibited reduced production of the proinflammatory mediators, such as TNF α, IL-1β, and MIF as well as inducible nitric-oxide synthase-mediated nitric oxide generation in both pancreatic islets and peripheral organs. The authors recommended VGX-1027 for further investigations as a prime candidate to treat this type of the autoimmune disease.
To suppress pulmonary inflammation, a novel glucocorticoids series of (GCs), 6α,9α-di-fluoro 3-substituted C-16,17-isoxazolines was designed [27]. A selected Cpd #15 compound inhibited LPS-induced nitric oxide release in Raw264.7 mouse macrophages, and TNF α-induced IL-8 production in human airway smooth muscle cells with a potency higher than that of Dexamethasone. The authors concluded that the compound displayed a pharmacokinetic and pharmacodynamic profile that was suitable for topical treatment of conditions that are associated with lung inflammatory reactions.
A series of new isoxazole derivatives of expected immunosuppressive activities was synthesized [29]. Following in vitro screening in the human cell models, the activity of a most active MZO-2 compound (ethyl N-(4-{[(2,4-dimethoxyphenyl)methyl]carbamoyl}-3-methyl-1,2-oxazol-5-yl)ethanimidate) in mouse in vivo models was evaluated. The compound, administered intraperitoneally, inhibited carrageenan-induced footpad edema, and the contact sensitivity in mice to oxazolone when applied in ointment, with a potency that was comparable to tacrolimus (Protopic®). The compound inhibited also expression of caspases 3, 8, and 9 in Jurkat cells.
Several new 3-methylisoxazol-5(4H)-one/2-hydroxy/mercapto-6-methylpyrimidin-4(5H)-one/3-methyl-1-substituted-1H-pyrazol-5(4H)-one substituted benzimidazole derivatives [30], were synthesized. A most potent representative of this series, 4-(2-(4-(1H-benzimidazol-2-yl)phenyl)hydrazono)-1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-one demonstrated significant analgesic activity, protection in carrageenan-induced footpad edema, efficient antibacterial, and moderate antiviral activities. Among the triazines, novel series [28] were synthesized, including isoxazoles with COX-2 inhibitory activity. To evaluate their anti-inflammatory activities, the compounds were investigated by the paw thickness inhibition assay. The most potent compound in the group of isoxazole derivatives that reduced the carrageenan-induced mice paw edema in comparison to Celecoxib, was compound 7a (N-(4-(isoxazol-5-yl)phenyl)-4,6-di(piperidin-1-yl)-1,3,5-triazin-2-amine) (51% inhibition of paw edema). Most of the compounds were even more potent than the reference drugs, such as: Celecoxib, Diclofenac, and Indomethacin. Analgesic and anti-inflammatory properties were also found when investigating isoxazole–mercaptobenzimidazole hybrids [31].
Indolyl–isoxazolidines are another category of compounds with potent anti-inflammatory-analgesic activities [32]. A selected compound, 9a, significantly inhibited LPS-induced TNF α and IL-6 production in macrophage THP-1 cells. The compound also caused analgesia and showed anti-inflammatory effects in the carrageenan test, with a potency that was comparable to that of indomethacin. Compound 9a was also effective in the protection of LPS-induced death in mice, indicating its potential usefulness as an analgesic/anti-inflammatory drug.

2.3. Immunoregulation

Following demonstration of the suppressive effects of HWA-486 (Leflunomide) compound in adjuvant-induced arthritis in rats using cyclophosphamide, prednisolone, and cyclosporine A as reference drugs [17], the studies were extended by using several in vivo and ex vivo methods that were aimed at the elucidation of differences between the mechanisms of the actions of HWA-486 and of reference immunosuppressors. The authors came to a conclusion [17] that the compound has inhibitory activity on T-cell-dependent B-cell immune responses, yet it does not affect T-cell-independent B-cells; thus T-cell responsiveness may not be affected. Therefore, these findings may explain the disease-modifying activity of HWA-486 in adjuvant-induced arthritic rats.
Immunoregulatory actions were described in a series of reports on the derivatives of phenylamides of 5-amino-3-methyl-4-isoxazolecarboxylic acid [44]. The activities of the compounds in the proliferative response of PBMC to PHA, and in LPS-induced cytokine production in the PBMC cultures were differential. The stimulatory or inhibitory effects depended strongly on the origin and location of substituents in the phenyl ring, as supported by QSAR (Quantitative Structure–Activity Relationship) studies. Similar conclusions could be drawn from in vivo and in vitro investigations on 4-imino derivatives of the 5-amino-3-methyl-1,2-oxazole-4-carbohydrazide and 5-amino-3-methylisoxazole[5,4-d]-6,7-dihydropyrimidine in mouse models [54].
Immunoregulatory properties were also observed with derivatives of 5-amino-3-methyl-1,2-oxazole-4-carbohydrazide [18]. The compound exhibited modulatory effects on T-cell subsets and levels of B-cells in lymphoid organs, and enhanced anti-SRBC antibody production in mice. The authors suggest its potential use in the treatment of autoimmune diseases, infections, or as an adjuvant for boosting the efficacy of vaccines.
The immunoregulatory properties of 2-(5-amino-3-methyl-1,2-oxazole-4-carbonyl)-N-(4-chlorophenyl)hydrazine-1-carbothioamide (06K compound) in mouse in vivo models were also investigated [19]. Interestingly, the actions of the compounds were differential, depending on a model used. The compound stimulated antibody production against SRBC, as measured by the numbers of antibody-forming cells, but the cellular immune response to OVA was decreased. Further, the compound significantly diminished carrageenan-induced foot pad edema. Phenotypic studies revealed that the immunoregulatory properties of the compound involved the mobilization of lymphopoiesis, and the generation of regulatory T cells. In another report with the application of in vitro models [20] 2-(5-amino-3-methyl-1,2-oxazole-4-carbonyl)-N-phenylhydrazine-1-carbothioamide (01K), and 2-(5-amino-3-methyl-1,2-oxazole-4-carbonyl)-N-(4-chlorophenyl)hydrazine-1-carbothioamide (06K) exhibited regulatory activity in the proliferation tests using cells from the thymus, spleen, and lymph nodes, as well as in the effects of the compounds on IL-1β, and the production of TNF-α in peritoneal cell cultures. These actions were associated with the different influence of the compounds on signaling protein expression in immature T cell Jurkat cell lines. Immunosuppressive isoxazole Leflunomide and a stimulatory RM-11 compound (1,7-dimethyl-8-oxo-1,2H-isoxazole[5,4-e]triazepine) were applied as reference drugs.
A study on the immunoregulatory properties of the selected 5-amino-3-methyl-4-isoxazolecarboxylic acid benzylamides [14], and its selected derivative MO5 (5-amino-3-methyl-N-[(4-methylphenyl)methyl]-1,2-oxazole-4-carboxamide), showed that the compounds inhibited the humoral immune response in vitro, stimulated the inductive phase of DTH in vivo, although it inhibited the eliciting phase of that response. The compound also inhibited the carrageenan skin reaction in mice, and inhibited LPS-induced TNF α production in human whole blood culture, as well as PHA-induced proliferation of PMBC.

2.4. Immunostimulation

Immunostimulatory actions of therapeutics are equally important as immunosuppressive ones, and they are invaluable in the restoration of immune functions in immunocompromised individuals that are subjected to antibiotics and chemotherapy. In a study with HAB-439 isoxazoline derivative the compound appeared to be an inhibitor of aminopeptidase [33]. HAB-439 stimulated the DTH response to Salmonella typhimurium and Listeria monocytogenes. It also restored a decreased DTH reaction that was caused by the ampicillin treatment of mice infected with L. monocytogenes.
Several immunostimulatory isoxazole derivatives were synthesized, and their potential therapeutic utility was evaluated by our research team. RM-11 (3,5-dimethyl-5,6-dihydro-4H-[1,2]oxazolo[5,4-e][1,2,4]triazepin-4-one) was found to potently stimulate both humoral and cellular immune response to SRBC in mice [34]. The compound also stimulated ConA-induced splenocyte proliferation. RM-11 showed no sign of toxicity when given to mice at a dose of 250 mg/kg body weight. The compound was subsequently investigated in a model of immunocompromised mice treated with cyclophosphamide (CP) [35]. In this model, the compound, given i.p. in repeatable doses, caused a rapid recovery of both antibody production against SRBC and DTH responses to OVA, in comparison with control mice. In addition, the compound accelerated the process of myelopoiesis as measured by the percentage of neutrophils and their precursors in the peripheral blood. The compound was also protective in the humoral immune response in vitro to SRBS suppressed by methotrexate. The phenotypic studies revealed that RM-11 preferentially increased the percentage of mature, single positive CD4+ and CD8+ T cells in the spleen of normal mice. Similar results were obtained with another T-cell tropic isoxazole derivative, 3,5-dimethyl-5,8-dihydro-4H-[1,2]oxazolo[5,4-e][1,2,4]triazepin-4-one hydrochloride (R 13), which also induced a significant increase of CD4+ T cells in the spleen, and in the lymph nodes of mice [37]. The compound significantly accelerated both the antibody production and the cellular immune response. Unlike RM-11, this compound decreased the content of myelocytic cells in the circulating blood, but increased the level of immature lymphocyte forms, indicating the preferential promotion of lymphopoiesis in CP-treated mice. In contrast to the two previously described compounds, 3,5-dimethyl-5,8-dihydro-4H-[1,2]oxazolo[5,4-e][1,2,4]triazepin-4-one (R-11) appeared to preferentially induce the recruitment of CD19+ B cells in normal mice [36]. Moreover, the development of both the humoral immune response to SRBC and DTH to OVA was also accelerated in CP-immunocompromised mice by this compound. The compound also stimulated IL-6 production, elicited by LPS in human whole blood cultures. We postulate that the above described compounds may be invaluable in the restitution of the immune function of patients undergoing chemotherapy. At present, the only therapeutic that is accepted for this purpose is granulocyte colony stimulating factor (Filgrastim®) [55]. However, the use of this cytokine has serious limitations, since it is costly and temperature-sensitive. In addition, this cytokine predominantly promotes myelopoiesis, the process is spontaneously recovered quickly [56]. However, the main problem with the reconstitution of the immune cell compartments of the chemotherapy patients are T- and B-cell compartments, where recovery takes much longer [57].
Other stimulatory izoxazole derivatives included 7-amino-3,5-dimethylisoxazole[5,4-e][1,3,4]-triazepin-4-one, showing the stimulatory effect on Con A-induced mouse splenocyte proliferation and cytokine production by the P388D1 macrophage cell line [58] and 2-(5-amino-3-methyl-1,2-oxazole-4-carbonyl)-N-(prop-2-en-1-yl)hydrazine-1-carbothioamide (compound M4) [12], which stimulated PHA-induced proliferation of human PBMC.
The aim of another study was to determine the immunomodulatory activity of 5-amino-3-methyl-1,2-oxazole-4-carbohydrazide in vitro [38]. The compound was not cytotoxic against reference cell lines, up to a concentration of 200 μg/mL. The compound stimulated the mitogen-induced proliferation of lymphocytes isolated from spleens and mesenteric lymph nodes when they were used alone and in combination with mitogens, and it increased LPS-elicited IL-1β production in peritoneal cell culture.
Interestingly, among salicylic acid derivatives containing an isoxazole ring, 3-(4-methoxyphenyl)-4-(3-hydroxy-4-carboxybenzoyl)-5-(3-chlorophenyl)-4,5-dihydroisoxazoline (8e), which demonstrated mitogenic activity towards human lymphocytes and mouse splenocytes, was found [39]. The ability of the compound to stimulate cell division was caused by increased IL-2 secretion. It seems that an advantage of this new mitogenic compound is that it should not bind to and inactivate sugar-containing biologically active proteins, in contrast to lectins (ConA, PHA). A property of binding to sugars in biologically active glycoproteins like lactoferrin [59] by protein mitogens (lectins) may hamper the interpretation of results deriving from models where mitogenic lectins are applied.

3. Conclusions

The isoxazole derivatives described herein have differential activities and mechanisms of action, and it may be applied in such disease and immunological disorders as inflammation, infection, autoimmune disorders, and impaired immune responsiveness. It is worthy to underline that many of the compounds, presented in this review, have higher potency in comparison to relevant reference drugs; thus they are potential therapeutics and they may replace registered drugs. Alternatively, they may enrich the pool of existing drugs in the market. Keeping in mind that even registered drugs are not completely devoid of side-effects and toxicity, the search for new compounds with the possible highest selectivity of action and the lowest toxicity is highly justified.

Funding

This research was funded by Wroclaw Medical University, grant number STD090.17.012.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Giomi, D.; Cordero, F.M.; Machetti, F. Comprehensive Heterocyclic Chemistry III; Katrizky, A.R., Ramsden, C.A., Scriven, E.F.V., Taylor, R.J.K., Eds.; Elsevier: Oxford, UK, 2008; pp. 365–486. [Google Scholar]
  2. Barmade, M.A.; Murumkar, P.R.; Sharma, M.K.; Yadav, M.R. Medicinal chemistry perspective of fused isoxazole derivatives. Curr. Top. Med. Chem. 2016, 16, 2863–2883. [Google Scholar] [CrossRef] [PubMed]
  3. Uto, Y. 1, 2-Benzisoxazole: A privileged structure with a potential for polypharmacology. Curr. Pharm. Des. 2016, 22, 3201–3211. [Google Scholar] [CrossRef] [PubMed]
  4. Sysak, A.; Obmińska-Mrukowicz, B. Isoxazole ring as a useful scaffold in a search for new therapeutic agents. Eur. J. Med. Chem. 2017, 137, 292–309. [Google Scholar] [CrossRef] [PubMed]
  5. Zhu, J.; Mo, J.; Lin, H.Z.; Chen, Y.; Sun, H.P. The recent progress of isoxazole in medicinal chemistry. Bioorg. Med. Chem. 2018, 23, 3065–3075. [Google Scholar] [CrossRef] [PubMed]
  6. Herrmann, M.L.; Schleyerbach, R.; Kirschbaum, B.J. Leflunomide: An immunomodulatory drug for the treatment of rheumatoid arthritis and other autoimmune diseases. Immunopharmacology 2000, 47, 273–289. [Google Scholar] [CrossRef]
  7. Satyanarayana, P.S.; Jain, N.K.; Singh, S.; Kulkarni, S.K. Effect of selective inhibition of cyclooxygenase-2 on lipopolysaccharide-induced hyperalgesia. Inflammopharmacology 2004, 12, 57–68. [Google Scholar] [CrossRef] [PubMed]
  8. Wagner, E.; Al-Kadasi, K.; Zimecki, M.; Sawka-Dobrowolska, W. Synthesis and pharmacological screening of derivatives of isoxazolo[4,5-d]pyrimidine. Eur. J. Med. Chem. 2008, 43, 2498–2504. [Google Scholar] [CrossRef] [PubMed]
  9. Ryng, S.; Machoń, Z.; Wieczorek, Z.; Zimecki, M.; Głowiak, T. Synthesis and structure elucidation of 5-aminomethinimino-3-methyl-4-isoxazolecarboxylic acid phenylamides and their immunological activity. Arch. Pharm. 1997, 330, 319–326. [Google Scholar] [CrossRef]
  10. Ryng, S.; Zimecki, M.; Maczyński, M.; Chodaczek, G.; Kocieba, M. Immunosuppressive activity of an isoxazolo[5,4-e]triazepine—Compound RM33. I. Effects on the humoral and cellular immune response in mice. Pharmacol. Rep. 2005, 57, 195–202. [Google Scholar] [PubMed]
  11. Maczyński, M.; Zimecki, M.; Drozd-Szczygieł, E.; Ryng, S. The synthesis, physicochemical properties and immunological activity of 5-amino-3-methylisoxazolo[5,4-d]4-pyrimidinone derivatives. Cell. Mol. Biol. Lett. 2005, 10, 613–623. [Google Scholar] [PubMed]
  12. Maczyński, M.; Zimecki, M.; Taraszkiewicz, M.; Ryng, S. Synthesis, immunological activity and computational study of 5-amino-3-methyl-4-isoxazolecarboxylic acid semicarbazides and thiosemicarbazides. Acta Pol. Pharm. 2008, 65, 543–549. [Google Scholar] [PubMed]
  13. Maczyński, M.; Ryng, S.; Artym, J.; Kocieba, M.; Zimecki, M.; Brudnik, K.; Jodkowski, J.T. New lead structures in the isoxazole system: Relationship between quantum chemical parameters and immunological activity. Acta Pol. Pharm. 2014, 71, 71–83. [Google Scholar] [PubMed]
  14. Maczyński, M.; Artym, J.; Kocieba, M.; Sochacka-Ćwikła, A.; Drozd-Szczygieł, E.; Ryng, S.; Zimecki, M. Synthesis and immunoregulatory properties of selected 5-amino-3-methyl-4 isoxazolecarboxylic acid benzylamides. Acta Pol. Pharm. 2016, 73, 1201–1211. [Google Scholar] [PubMed]
  15. Płoszaj, P.; Regiec, A.; Ryng, S.; Piwowar, A.; Kruzel, M.L. Influence of 5-amino-3-methyl-4-isoxazolecarbohydrazide on selective gene expression in Caco-2 cultured cells. Immunopharmacol. Immunotoxicol. 2016, 38, 486–494. [Google Scholar] [CrossRef] [PubMed]
  16. Mączyński, M.; Borska, S.; Mieszała, K.; Kocięba, M.; Zaczyńska, E.; Kochanowska, I.; Zimecki, M. Synthesis, immunosuppressive properties, and mechanism of action of a new isoxazole derivative. Molecules 2018, 23, 1545. [Google Scholar] [CrossRef] [PubMed]
  17. Bartlett, R.R.; Schleyerbach, R. Immunopharmacological profile of a novel isoxazol derivative, HWA 486, with potential antirheumatic activity—I. Disease modifying action on adjuvant arthritis of the rat. Int. J. Immunopharmacol. 1985, 7, 7–18. [Google Scholar] [CrossRef]
  18. Drynda, A.; Obmińska-Mrukowicz, B.; Mączyński, M.; Ryng, S. The effect of 5-amino-3-methyl-4-isoxazolecarboxylic acid hydrazide on lymphocyte subsets and humoral immune response in SRBC-immunized mice. Immunopharmacol. Immunotoxicol. 2015, 37, 148–157. [Google Scholar] [CrossRef] [PubMed]
  19. Drynda, A.; Obmińska-Mrukowicz, B.; Zaczyńska, E.; Zimecki, M.; Ryng, S.; Mączyński, M. Immunoregulatory effects of 4-(4-chlorophenyl)-1-(5-amino-3-methylisoxazole-4-carbonyl)-thiosemicarbazide (06K) in non-immunized and SRBC-immunized mice. J. Pharm. Pharmacol. 2016, 68, 1613–1620. [Google Scholar] [CrossRef] [PubMed]
  20. Drynda, A.; Obmińska-Mrukowicz, B.; Zaczyńska, E.; Zimecki, M.; Kochanowska, I.; Ryng, S.; Mączyński, M. 5-Amino-3-methyl-4-isoxazolecarboxylic acid hydrazide derivatives with in vitro immunomodulatory activities. Chem. Biol. Drug Des. 2017, 89, 705–713. [Google Scholar] [CrossRef] [PubMed]
  21. Machoń, Z.; Ryng, S. Synthesis and biological properties of 5-benzoylamino-3-methyl-4-isoxazolocarboxylic acid derivatives. Arch. Immunol. Ther. Exp. 1981, 29, 813–821. [Google Scholar]
  22. Stojanovic, I.; Cuzzocrea, S.; Mangano, K.; Mazzon, E.; Miljkovic, D.; Wang, M.; Donia, M.; Al Abed, Y.; Kim, J.; Nicoletti, F.; et al. In vitro, ex vivo and in vivo immunopharmacological activities of the isoxazoline compound VGX-1027: Modulation of cytokine synthesis and prevention of both organ-specific and systemic autoimmune diseases in murine models. Clin. Immunol. 2007, 123, 311–323. [Google Scholar] [CrossRef] [PubMed]
  23. Andrzejak, V.; Muccioli, G.G.; Body-Malapel, M.; El Bakali, J.; Djouina, M.; Renault, N.; Chavatte, P.; Desreumaux, P.; Lambert, D.M.; Millet, R. New FAAH inhibitors based on 3-carboxamido-5-aryl-isoxazole scaffold that protect against experimental colitis. Bioorg. Med. Chem. 2011, 19, 3777–3786. [Google Scholar] [CrossRef] [PubMed]
  24. Rakesh, K.S.; Jagadish, S.; Balaji, K.S.; Zameer, F.; Swaroop, T.R.; Mohan, C.D.; Jayarama, S.; Rangappa, K.S. 3,5-disubstituted isoxazole derivatives: Potential inhibitors of inflammation and Cancer. Inflammation 2016, 39, 269–280. [Google Scholar] [CrossRef] [PubMed]
  25. Banoglu, E.; Çelikoğlu, E.; Völker, S.; Olgaç, A.; Gerstmeier, J.; Garscha, U.; Çalışkan, B.; Schubert, U.S.; Carotti, A.; Macchiarulo, A.; Werz, O. 4,5-diarylisoxazol-3-carboxylic acids: A new class of leukotriene biosynthesis inhibitors potentially targeting 5-lipoxygenase-activating protein (FLAP). Eur. J. Med. Chem. 2016, 4, 1–10. [Google Scholar] [CrossRef] [PubMed]
  26. Russell, K.E.; Chung, K.F.; Clarke, C.J.; Durham, A.L.; Mallia, P.; Footitt, J.; Johnston, S.L.; Barnes, P.J.; Hall, S.R.; Simpson, K.D.; et al. The MIF antagonist ISO-1 attenuates corticosteroid-insensitive inflammation and airways hyperresponsiveness in an ozone-induced model of COPD. PLoS ONE 2016, 11, 0146102. [Google Scholar] [CrossRef] [PubMed]
  27. Ghidini, E.; Capelli, A.M.; Carnini, C.; Cenacchi, V.; Marchini, G.; Virdis, A.; Italia, A.; Facchinetti, F. Discovery of a novel isoxazoline derivative of prednisolone endowed with a robust anti-inflammatory profile and suitable for topical pulmonary administration. Steroids 2015, 95, 88–95. [Google Scholar] [CrossRef] [PubMed]
  28. Elshemy, H.A.H.; Abdelall, E.K.A.; Azouz, A.A.; Moawad, A.; Ali, W.A.M.; Safwat, N.M. Synthesis, anti-inflammatory, cyclooxygenases inhibitions assays and histopathological study of poly-substituted 1,3,5-triazines: Confirmation of regiospecific pyrazole cyclization by HMBC. Eur. J. Med. Chem. 2017, 127, 10–21. [Google Scholar] [CrossRef] [PubMed]
  29. Mączyński, M.; Artym, J.; Kocięba, M.; Kochanowska, I.; Ryng, S.; Zimecki, M. Anti-inflammatory properties of an isoxazole derivative—MZO-2. Pharmacol. Rep. 2016, 68, 894–902. [Google Scholar] [CrossRef] [PubMed]
  30. Chikkula Krishna, V.; Sundararajan, R. Analgesic, anti-inflammatory, and antimicrobial activities of novel isoxazole/pyrimidine/pyrazole substituted benzimidazole analogs. Med. Chem. Res. 2017, 26, 3026–3037. [Google Scholar] [CrossRef]
  31. Kankala, S.; Kankala, R.K.; Gundepaka, P.; Thota, N.; Nerella, S.; Gangula, M.R.; Guguloth, H.; Kagga, M.; Vadde, R.; Vasam, C.S. Regioselective synthesis of isoxazole-mercaptobenzimidazole hybrids and their in vivo analgesic and anti-inflammatory activity studies. Bioorg. Med. Chem. Lett. 2013, 23, 1306–1309. [Google Scholar] [CrossRef] [PubMed]
  32. Singh, G.; Singh, G.; Bhatti, R.; Gupta, M.; Kumar, A.; Sharma, A.; Singh Ishar, M.P. Indolyl-isoxazolidines attenuate LPS-stimulated pro-inflammatory cytokines and increase survival in a mouse model of sepsis: Identification of potent lead. Eur. J. Med. Chem. 2018, 153, 56–64. [Google Scholar] [CrossRef] [PubMed]
  33. Dickneite, G.; Schwab, W.; Schorlemmer, H.U.; Gebert, U.; Sedlacek, H.H. Effect of the new immunostimulator HAB 439 on cell-mediated immunity against intracellular bacteria. Int. J. Immunopharmacol. 1991, 13, 541–548. [Google Scholar] [CrossRef]
  34. Ryng, S.; Sonnenberg, Z.; Zimecki, M. RM-11, a new izoxasole derivative, is a potent stimulator of the humoral and cellular immune responses in mice. Arch. Immunol. Ther. Exp. 2000, 48, 127–131. [Google Scholar]
  35. Zimecki, M.; Artym, J.; Ryng, S.; Obmińska-Mrukowicz, B. RM-11, an isoxazole derivative, accelerates restoration of the immune function in mice treated with cyclophosphamide. Pharmacol. Rep. 2008, 60, 183–189. [Google Scholar] [PubMed]
  36. Zimecki, M.; Artym, J.; Kocięba, M.; Obmińska-Mrukowicz, B.; Mączyński, M.; Ryng, S. Restoration of immune system function is accelerated in immunocompromised mice by the B-cell-tropic isoxazole R-11. Pharmacol. Rep. 2012, 64, 403–411. [Google Scholar] [CrossRef]
  37. Zimecki, M.; Artym, J.; Kocięba, M.; Obmińska-Mrukowicz, B.; Mączyński, M.; Ryng, S. Immune function in cyclophosphamide-treated mice is restored by the T-cell-tropic isoxazole derivative R-13. J. Immunotoxicol. 2015, 12, 322–329. [Google Scholar] [CrossRef] [PubMed]
  38. Drynda, A.; Mączyński, M.; Ryng, S.; Obmińska-Mrukowicz, B. In vitro immunomodulatory effects of 5-amino-3-methyl-4-isoxazolecarboxylic acid hydrazide on the cellular immune response. Immunopharmacol. Immunotoxicol. 2014, 36, 150–157. [Google Scholar] [CrossRef] [PubMed]
  39. Puttaswamy, N.; Pavan Kumar, G.S.; Al-Ghorbani, M.; Vigneshwaran, V.; Prabhakar, B.T.; Khanum, S.A. Synthesis and biological evaluation of salicylic acid conjugated isoxazoline analogues on immune cell proliferation and angiogenesis. Eur. J. Med. Chem. 2016, 114, 153–161. [Google Scholar] [CrossRef] [PubMed]
  40. Kremer, J.M. Methotrexate and leflunomide: Biochemical basis for combination therapy in the treatment of rheumatoid arthritis. Semin. Arthritis Rheum. 1999, 29, 14–26. [Google Scholar] [CrossRef]
  41. Furst, D.E. Innovative treatment approaches for rheumatoid arthritis. Cyclosporin, leflunomide and nitrogen mustard. Baillieres Clin. Rheumatol. 1995, 9, 711–729. [Google Scholar] [CrossRef]
  42. Schug, S.A.; Parsons, B.; Li, C.; Xia, F. The safety profile of parecoxib for the treatment of postoperative pain: A pooled analysis of 28 randomized, double-blind, placebo-controlled clinical trials and a review of over 10 years of postauthorization data. J. Pain Res. 2017, 10, 2451–2459. [Google Scholar] [CrossRef] [PubMed]
  43. Zhang, J.; Ding, E.L.; Song, Y. Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events meta-analysis of randomized trials. J. Am. Med. Assoc. 2006, 296, 1619–1632. [Google Scholar] [CrossRef] [PubMed]
  44. Ryng, S.; Machoń, Z.; Wieczorek, Z.; Zimecki, M. Synthesis and immunological activity of new 5-amino-3-methyl 4-amido and 4-ureilene isoxazole derivatives. Pharmazie 1999, 54, 359–361. [Google Scholar] [CrossRef] [PubMed]
  45. Maczyński, M.; Jezierska, A.; Zimecki, M.; Ryng, S. Synthesis, immunological activity and theoretical study of new 5-substituted 3-methylisoxazole[5,4-d] 1,2,3-triazin-4-one derivatives. Acta Pol. Pharm. 2003, 60, 147–150. [Google Scholar] [PubMed]
  46. Jezierska, A.; Maczyński, M.; Koll, A.; Ryng, S. Structure/activity investigations of 5-substituted 3-methylisoxazole[5,4-d]1, 2, 3-triazin-4-one derivatives. Arch. Pharm. 2004, 337, 81–89. [Google Scholar] [CrossRef] [PubMed]
  47. Zimecki, M.; Mączyński, M.; Artym, J.; Ryng, S. Closely related isoxazoles may exhibit opposite immunological activities. Acta Pol. Pharm. 2008, 65, 793–794. [Google Scholar] [PubMed]
  48. Zimecki, M.; Ryng, S.; Maczyński, M.; Chodaczek, G.; Kocieba, M.; Kuryszko, J.; Kaleta, K. Immunosuppressory activity of an isoxazolo[5,4-e]triazepine-compound RM-33 II. Effects on the carrageenan-induced inflammation. Pharmacol. Rep. 2006, 58, 236–241. [Google Scholar] [PubMed]
  49. Kalgutkar, A.S.; Nguyen, H.T.; Vaz, A.D.; Doan, A.; Dalvie, D.K.; McLeod, D.G.; Murray, J.C. In vitro metabolism studies on the isoxazole ring scission in the anti-inflammatory agent lefluonomide to its active alpha-cyanoenol metabolite A771726: Mechanistic similarities with the cytochrome P450-catalyzed dehydration of aldoximes. Drug Metab. Dispos. 2003, 31, 1240–1250. [Google Scholar] [CrossRef] [PubMed]
  50. Hamilton, L.C.; Vojnovic, I.; Warner, T.D. A771726, the active metabolite of leflunomide, directly inhibits the activity of cyclo-oxygenase-2 in vitro and in vivo in a substrate-sensitive manner. Br. J. Pharmacol. 1999, 127, 1589–1596. [Google Scholar] [CrossRef] [PubMed]
  51. Yao, H.W.; Li, J.; Chen, J.Q.; Xu, S.Y. A 771726, the active metabolite of leflunomide, inhibits TNF-alpha and IL-1 from Kupffer cells. Inflammation 2004, 28, 97–103. [Google Scholar] [CrossRef] [PubMed]
  52. Leng, L.; Chen, L.; Fan, J.; Greven, D.; Arjona, A.; Du, X.; Austin, D.; Kashgarian, M.; Yin, Z.; Huang, X.R.; et al. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J. Immunol. 2011, 186, 527–538. [Google Scholar] [CrossRef] [PubMed]
  53. Stosic-Grujicic, S.; Cvetkovic, I.; Mangano, K.; Fresta, M.; Maksimovic-Ivanic, D.; Harhaji, L.; Popadic, D.; Momcilovic, M.; Miljkovic, D.; Kim, J.; et al. A potent immunomodulatory compound, (S,R)-3-Phenyl-4,5-dihydro-5-isoxazole acetic acid, prevents spontaneous and accelerated forms of autoimmune diabetes in NOD mice and inhibits the immunoinflammatory diabetes induced by multiple low doses of streptozotocin in CBA/H mice. J. Pharmacol. Exp. Ther. 2007, 320, 1038–1049. [Google Scholar] [PubMed]
  54. Ryng, S.; Zimecki, M.; Fedorowicz, A.; Jezierska, A. Reactions of 5-amino-3-methylisoxazole-4-carboxylic acid hydrazide with carbonyl compounds: Immunological activity and QSAR studies of products. Arch. Pharm. 2001, 334, 71–78. [Google Scholar] [CrossRef]
  55. Mitchell, S.; Li, X.; Woods, M.; Garcia, J.; Hebard-Massey, K.; Barron, R.; Samuel, M. Comparative effectiveness of granulocyte colony-stimulating factors to prevent febrile neutropenia and related complications in cancer patients in clinical practice: A systematic review. J. Oncol. Pharm. Pract. 2016, 22, 702–716. [Google Scholar] [CrossRef] [PubMed]
  56. Renwick, W.; Pettengell, R.; Green, M. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: Twenty years of clinical experience. BioDrugs 2009, 23, 175–186. [Google Scholar] [CrossRef] [PubMed]
  57. Talmadge, J.E.; Jackson, J.D.; Borgeson, C.D.; Perry, G.A. Differential recovery of polymorphonuclear neutrophils, B- and T-cell sub-populations in the thymus, bone marrow, spleen and blood of mice following split-dose polychemotherapy. Cancer Immunol. Immunother. 1994, 39, 59–67. [Google Scholar] [CrossRef] [PubMed]
  58. Drozd-Szczygieł, E.; Ryng, S.; Zimecki, M. 7-amino-3,5-dimethylisoxazole [5,4-e] [1,3,4]-triazepin-4-one- a potential new lead structure: Its structure, physicochemical properties and biological activity. Acta Pol. Pharm. 2004, 61, 84–85. [Google Scholar] [CrossRef] [PubMed]
  59. Zimecki, M.; Stepniak, D.; Szynol, A.; Kruzel, M.L. Lactoferrin regulates proliferative response of human peripheral blood mononuclear cells to phytohemagglutinin and mixed lymphocyte reaction. Arch. Immunol. Ther. Exp. 2001, 49, 147–154. [Google Scholar]
Sample Availability: Not available.
Table 1. Isoxazole derivatives with potential application in therapy.
Table 1. Isoxazole derivatives with potential application in therapy.
CompoundStructureActivityMolecular/Cellular Mechanism of ActionReference Number
Immunosuppressive actions
HWA-486/Leflunomide 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamideMolecules 23 02724 i001Immunosuppressive and anti-inflammatory regulation of autoimmune lymphocytesCOX-2 inhibitor, non-cytotoxic inhibitor of dihydroorotate dehydrogenase[6]
ParecoxibMolecules 23 02724 i002Anti-inflammatory registered drugCOX-2 inhibitor[7]
8g/5-(4-amino-5-benzoyl-1,2-oxazol-3-yl)-N-[(pyridin-4-yl)methyl]-1,3,4-oxadiazole-2-carboxamideMolecules 23 02724 i003Inhibits the proliferative response of mouse splenocytes to concanavalin A,
suppresses the humoral immune response		N.D.[8]
10f/5-(5-amino-7-phenyl[1,2]oxazolo[4,5-d]pyrimidin-3-yl)-N-[(pyridin-3-yl)methyl]-1,3,4-oxadiazole-2-carboxamideMolecules 23 02724 i004Stimulates mitogen-induced proliferation of mouse splenocytes, suppresses DTHN.D.[8]
4d/5-(2-hydroxyethyl)piperazinomethinimino-3-methyl-4-isoxazolecarboxylic acid 4-(4-ethoxyphenyl)-amideMolecules 23 02724 i005Inhibits the DTH and humoral immune response to SRBC in vitro and in vivoN.D.[9]
RM-33/3,5,7-trimethyl-5,6,7,8-tetrahydro-4H-[1,2]oxazolo[5,4-e][1,2,4]triazepin-4-oneMolecules 23 02724 i006Inhibits LPS-induced TNF-α and IL-6 activity inhibits antibody production* Stimulation of caspase 9 expression in thymocytes and splenocytes and Fas in bone marrow cells and splenocytes, inhibition of ERK1 and p38g in bone marrow cells[10]
1020/5-{[(4-hydroxyphenyl)methylidene]amino}-3-methyl[1,2]oxazolo[5,4-d]pyrimidin-4(5H)-oneMolecules 23 02724 i007Displays strong immunosuppressive action, inhibits polyclonal antibody productionN.D.[11]
1025/5-(cyclohexylideneamino)-3-methyl[1,2]oxazolo[5,4-d]pyrimidin-4(5H)-oneMolecules 23 02724 i008Shows immunosuppressive property, lowers polyclonal antibody productionN.D.[11]
M5/2-[(5-amino-3-methylisoxazol-4-yl)carbonyl]-N-(4-chlorophenyl)hydrazinecarboxamideMolecules 23 02724 i009Inhibits antibody production in miceN.D.[12]
RM56/5-(5-amino-3-methyl-1,2-oxazol-4-yl)-1,3,4-oxadiazol-2-amineMolecules 23 02724 i010Inhibits the humoral immune response, the carrageenan reaction and proliferation of lymphocytesN.D.[13]
MO5/5-amino-3-methyl-N-[(4-methylphenyl)methyl]-1,2-oxazole-4-carboxamideMolecules 23 02724 i011Inhibits the humoral immune response in vitroInhibitor of TNFα production[14]
5-amino-3-methyl-1,2-oxazole-4-carbohydrazideMolecules 23 02724 i012Modulates the content of T cell subsets and B cells in lymphoid organs, and elevates the humoral immune response in miceUpregulation of fractalkine (CX3CL1) and IL-17F, and downregulation of IL-10 and TLR4[15]
MM3/5-amino-N′-[2-(2,4-dihydroxyphenyl)ethylidene]-N,3-dimethyl-1,2-oxazole-4-carbohydrazideMolecules 23 02724 i013Inhibits the mitogen-induced proliferation of PBMC and LPS-induced TNF α production in human blood cell cultureStrong increases in the expression of caspases, Fas, and NF-kB1[16]
Immune regulators
HWA-486/Leflunomide 5-methyl-N-[4-(trifluoromethyl)phenyl]-1,2-oxazole-4-carboxamide Molecules 23 02724 i014Suppresses T cell-dependent B-cell responses, does not affect T-independent B-cell functionCOX-2 inhibitor[17]
5-amino-3-methyl-1,2-oxazole-4-carbohydrazideMolecules 23 02724 i015Modulates T cell subset composition and the levels of B cells in lymphoid organs, and enhances anti-SRBC humoral immune responses in miceModulation of T and B cell content in lymphatic organs[18]
06K/2-(5-amino-3-methyl-1,2-oxazole-4-carbonyl)-N-(4-chlorophenyl)hydrazine-1-carbothioamideMolecules 23 02724 i016Induces lymphopoiesis and the generation of regulatory T-cells, stimulates the humoral immune response, decreases the DTH reactionIncreases percentage of CD8+ and regulatory CD4+CD25+Fox3+ T cells in spleens and lymph nodes[19]
01K/2-(5-amino-3-methyl-1,2-oxazole-4-carbonyl)-N-phenylhydrazine-1-carbothioamideMolecules 23 02724 i017Regulates proliferation of thymocytes, splenocytes, and lymph node cellsRegulation of IL-1β and TNF-α production in peritoneal cell cultures[20]
MO5/5-amino-3-methyl-N-[(4-methylphenyl)methyl]-1,2-oxazole-4-carboxamideMolecules 23 02724 i018Inhibits the humoral immune response in vitroInhibition of TNFα production[14]
Anti-inflammatory
5-amino-N-(4-ethoxyphenyl)-3-methyl-1,2-oxazole-4-carboxamideMolecules 23 02724 i019Lowers carrageenan-induced paw edema, exhibits antibacterial activityN.D.[21]
5-benzamido-N-(4-chlorophenyl)-3-methyl-1,2-oxazole-4-carboxamideMolecules 23 02724 i020Shows anti-inflammatory activity in the carrageenan-induced reaction, has antibacterial propertiesN.D.[21]
VGX-1027 (S,R)-(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)acetic acidMolecules 23 02724 i021Suppresses carrageenan-induced pleurisy, LPS-induced lethality, and type II-collagen-induced arthritisSuppression of TNF α, IL-1β, MIF,
inhibition of NFκB and p38, and
upregulation of ERK signaling		[22]
N-(2-(Benzo[d][1,3]dioxol-5-yl)ethyl)-5-(biphen-4-yl)-isoxazole-3-carboxamideMolecules 23 02724 i022Protects against experimental colitisInhibition of FAAH (fatty acid amide hydrolase))[23]
2b/5-(3-methylthiophen-2-yl)-3-(3,4,5-trimethoxyphenyl)-1,2-oxazoleMolecules 23 02724 i023Inhibits tumor growth, peritoneal angiogenesis, and ascite formation in Erlich carcinoma mouse modelInhibitory activity toward lipooxygenase (LOX) and COX-2[24]
39/4-(4-Chlorophenyl)-5-[4-(quinolin-2-ylmethoxy)phenyl]isoxazol-3-carboxylic acid
40/4-(4-Chlorophenyl)-5-[4-(benzothiazol-2-ylmethoxy)phenyl]
isoxazol-3-carboxylic acid		Molecules 23 02724 i024Anti-inflammatory agentInhibitory activity against cellular 5-LO (5-lipoxygenase) product synthesis[25]
ISO-1/(S,R)-methyl [3-(4-oxocyclohexa-2,5-dien-1-ylidene)-1,2-oxazolidin-5-yl]acetateMolecules 23 02724 i025Blocks corticosteroid-insensitive lung inflammation and airway hyper-responsiveness) suppresses lung inflammation in ozone-exposed mice, in contrast to dexamethasoneInhibition of migration inhibitory factor (MIF) function[26]
Cpd #15/(16S,17R)-30-bromo-6,9-difluoro-11b,21-dihydroxy-40H-pregna-1,4-dieno[16,17-d]isoxazole-3,20-dioneMolecules 23 02724 i026Inhibits eosinophilic infiltration in a model of allergen-induced pulmonary inflammation in ratsInhibits LPS-induced nitric oxide production[27]
7a/N-(4-(isoxazol-5-yl)phenyl)-4,6-di(piperidin-1-yl)-1,3,5-triazin-2-amineMolecules 23 02724 i027Reduces carrageenan-induced mice paw edema in comparison to celecoxibCOX-2 inhibitor[28]
MZO-2/ethyl N-(4-{[(2,4-dimethoxyphenyl)methyl]carbamoyl}-3-methyl-1,2-oxazol-5-yl)ethanimidateMolecules 23 02724 i028Inhibits carrageenan-induced footpad inflammation and the contact sensitivity in mice to oxazolone when applied in ointmentSuppression of LPS-induced TNFα, and the expression of caspases 3, 8, and 9 in Jurkat cells[29]
4-(2-(4-(1H-benzimidazol-2-yl)phenyl)hydrazono)-1-(4-chlorophenyl)-3-methyl-1H-pyrazol-5(4H)-oneMolecules 23 02724 i029Demonstrates analgesic activity and protection in paw edema test, is comparable with that of the reference drug DiclofenacN.D.[30]
Isoxazole-mercaptobenzimidazole hybridsMolecules 23 02724 i030Is analgesic and anti-inflammatory activity in vivoN.D.[31]
(3S,3aR,6aS)-5-benzyl-3-(1H-indol-3-yl)-2-phenyl-hexahydro-2H-pyrrolo[3,4-d][1,2]oxazole-4,6-dione (9ª)Molecules 23 02724 i031Increases survival in a mouse model of sepsisInhibition of LPS-induced TNF α and IL-6 production in macrophage THP-1 cells[32]
Immunostimulatory
HAB-439/(3-phenyl-4,5-dihydro-1,2-oxazol-5-yl)phosphonic acidMolecules 23 02724 i032Stimulates DTH response to Salmonella typhimurium and Listeria monocytogenesInhibitor of aminopeptidase B[33]
RM-11/3,5-dimethyl-5,6-dihydro-4H-[1,2]oxazolo[5,4-e][1,2,4]triazepin-4-oneMolecules 23 02724 i033Stimulates mitogen-induced splenocyte proliferation and accelerates the restoration of the humoral and cellular immune response in cyclophosphamide-treated miceN.D.[34,35]
R-11/3,5-dimethyl-5,8-dihydro-4H-[1,2]oxazolo[5,4-e][1,2,4]triazepin-4-oneMolecules 23 02724 i034 (base)Recruits CD19+ B and accelerates the development of both types of the immune response in immunocompromised miceStimulation of LPS-induced IL-6 production in human whole blood cultures[36]
R-13/3,5-dimethyl-5,8-dihydro-4H-[1,2]oxazolo[5,4-e][1,2,4]triazepin-4-one hydrochlorideMolecules 23 02724 i035 + HCL (salt)Recruits CD4+ T cells and accelerates the restoration of both types of the immune response in immunocompromised miceN.D.[37]
M4/.2-(5-amino-3-methyl-1,2-oxazole-4-carbonyl)-N-(prop-2-en-1-yl)hydrazine-1-carbothioamideMolecules 23 02724 i036Enhances the mitogen-induced proliferative response of human PBMCN.D.[12]
5-amino-3-methyl-1,2-oxazole-4-carbohydrazideMolecules 23 02724 i037Stimulates mitogen-induced proliferation of splenocytes and lymph node cellsIncrease of LPS-induced induced IL-1β production by peritoneal cells[38]
8e/3-(4-methoxyphenyl)-4(3-hydroxy-4-carboxybenzoyl)-5-(3-chlorophenyl)-4,5-dihydrodihydroisoxazolineMolecules 23 02724 i038Augments the proliferative response of human and mouse lymphocytesIncreased IL-2 secretion[39]
* Recently established, unpublished; N.D.—not defined.

Share and Cite

MDPI and ACS Style

Zimecki, M.; Bąchor, U.; Mączyński, M. Isoxazole Derivatives as Regulators of Immune Functions. Molecules 2018, 23, 2724. https://doi.org/10.3390/molecules23102724

AMA Style

Zimecki M, Bąchor U, Mączyński M. Isoxazole Derivatives as Regulators of Immune Functions. Molecules. 2018; 23(10):2724. https://doi.org/10.3390/molecules23102724

Chicago/Turabian Style

Zimecki, Michał, Urszula Bąchor, and Marcin Mączyński. 2018. "Isoxazole Derivatives as Regulators of Immune Functions" Molecules 23, no. 10: 2724. https://doi.org/10.3390/molecules23102724

APA Style

Zimecki, M., Bąchor, U., & Mączyński, M. (2018). Isoxazole Derivatives as Regulators of Immune Functions. Molecules, 23(10), 2724. https://doi.org/10.3390/molecules23102724

Article Metrics

Back to TopTop